aspartocyclase gene therapy (University of Medicine and Dentistry of New Jersey/Academic institutions)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameaspartocyclase gene therapy (University of Medicine and Dentistry of New Jersey/Academic institutions)
Drug Alias NameASPA gene therapy (University of Medicine and Dentistry of New Jersey/Academic institutions)LPD-ASPA
ClassificationBiologics
Mechanisms of ActionASPA gene stimulants
TargetsAspartoacylase
Therapy Area/IndicationsCanavan Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew Zealand
CombinationsNo
Global Highest StatusDiscontinued (Clinical)
Highest Status in ChinaN/A
Originator CompaniesYale University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsCanavan Disease

Other Information

ATC CodeN/A
Related LinksN/A